A positron emission tomography study of the serotonin1B receptor effect of electroconvulsive therapy for severe major depressive episodes.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 11 2021
Historique:
received: 12 05 2021
revised: 09 07 2021
accepted: 12 07 2021
pubmed: 1 8 2021
medline: 30 10 2021
entrez: 31 7 2021
Statut: ppublish

Résumé

Electroconvulsive therapy (ECT) is an effective treatment for depressive disorders, although its molecular mechanism of action is unknown. The serotonin 1B (5-HT The objective of this longitudinal PET study was to examine the effect of ECT for depression on 5-HT Thirteen patients completed the study according to protocol. Eleven out of thirteen patients responded to ECT. 5-HT Albeit representative of a PET study, the sample size is still small and there are potential confounding effects of medication. Increased 5-HT

Sections du résumé

BACKGROUND
Electroconvulsive therapy (ECT) is an effective treatment for depressive disorders, although its molecular mechanism of action is unknown. The serotonin 1B (5-HT
METHODS
The objective of this longitudinal PET study was to examine the effect of ECT for depression on 5-HT
RESULTS
Thirteen patients completed the study according to protocol. Eleven out of thirteen patients responded to ECT. 5-HT
LIMITATIONS
Albeit representative of a PET study, the sample size is still small and there are potential confounding effects of medication.
CONCLUSIONS
Increased 5-HT

Identifiants

pubmed: 34332365
pii: S0165-0327(21)00739-4
doi: 10.1016/j.jad.2021.07.060
pii:
doi:

Substances chimiques

Ketamine 690G0D6V8H

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

645-651

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Mikael Tiger (M)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Sweden.; Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. Electronic address: mikael.tiger@ki.se.

Martin Gärde (M)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Sweden.

Amane Tateno (A)

Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Granville J Matheson (GJ)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Sweden.

Takeshi Sakayori (T)

Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Tsuyoshi Nogami (T)

Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Hiroki Moriya (H)

Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Katarina Varnäs (K)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Sweden.

Ryosuke Arakawa (R)

Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Yoshiro Okubo (Y)

Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH